BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...
BioCentury | Oct 21, 2019
Emerging Company Profile

Inscopix: scoping out better preclinical models via live brain imaging

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest CLRN1 gene therapy could help treat hearing loss in Usher syndrome type 3A, which is caused by CLRN1 mutations. In a hair cell-specific CLRN1 knockout mouse model of Usher...
BioCentury | May 3, 2018
Emerging Company Profile

Come together

...in multiple target proteins, leading to proteostatic collapse and eventual bacterial cell death, said CEO Els...
...$32.7 million) Investors: LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+ CEO: Els...
BioCentury | Sep 1, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
BioCentury | Aug 29, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
BioCentury | Jul 11, 2017
Preclinical News

Amino acid transporter linked to depression

In a paper published in The Journal of Neuroscience , scientists showed that reduction of solute carrier family 6 member 15 (SLC6A15) , a neutral amino acid transporter, in the nucleus accumbens is linked to increased susceptibility...
BioCentury | Feb 1, 2017
Emerging Company Profile

Evoking exosomes

Exosomes are emerging as one of the newest technologies for creating diagnostics and delivering therapeutics, primarily in cancer. Evox Therapeutics Ltd. is joining the growing list of start-ups, using science from exosome pioneer Matthew Wood...
BioCentury | Oct 18, 2016
Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
Items per page:
1 - 10 of 128
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...
BioCentury | Oct 21, 2019
Emerging Company Profile

Inscopix: scoping out better preclinical models via live brain imaging

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest CLRN1 gene therapy could help treat hearing loss in Usher syndrome type 3A, which is caused by CLRN1 mutations. In a hair cell-specific CLRN1 knockout mouse model of Usher...
BioCentury | May 3, 2018
Emerging Company Profile

Come together

...in multiple target proteins, leading to proteostatic collapse and eventual bacterial cell death, said CEO Els...
...$32.7 million) Investors: LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+ CEO: Els...
BioCentury | Sep 1, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
BioCentury | Aug 29, 2017
Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
BioCentury | Jul 11, 2017
Preclinical News

Amino acid transporter linked to depression

In a paper published in The Journal of Neuroscience , scientists showed that reduction of solute carrier family 6 member 15 (SLC6A15) , a neutral amino acid transporter, in the nucleus accumbens is linked to increased susceptibility...
BioCentury | Feb 1, 2017
Emerging Company Profile

Evoking exosomes

Exosomes are emerging as one of the newest technologies for creating diagnostics and delivering therapeutics, primarily in cancer. Evox Therapeutics Ltd. is joining the growing list of start-ups, using science from exosome pioneer Matthew Wood...
BioCentury | Oct 18, 2016
Financial News

Ysios closes EUR 126.4M fund

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...
Items per page:
1 - 10 of 128